ASLN Aslan Pharmaceuticals ADS

ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

SAN MATEO, Calif. and SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will present a company update at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY, from June 7 to 9, 2023. Presentation details are below. ASLAN management will also be available for one-on-one meetings on the day of the presentation.

Jefferies Global Healthcare Conference Presentation Information

Format: Live presentation with webcast link

Presenter: Carl Firth, CEO, ASLAN Pharmaceuticals

Date: Thursday, June 8, 2023

Time: 4:30 PM EDT

A replay of the presentation can be accessed directly at this and will be posted to the Investor Relations section of ASLAN’s and available for 90 days.

Please contact your sales representative at Jefferies to register for a meeting with the Company.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease. Eblasakimab is being investigated in a global Phase 2b trial of moderate-to-severe AD patients with topline readout expected in early July 2023. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a proof-of-concept trial with an interim readout expected in 1Q 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the or follow ASLAN on .

Media and IR contacts

Emma Thompson 

Spurwing Communications 

Tel:  

Email:  



Ashley R. Robinson 

LifeSci Advisors, LLC 

Tel: +1 (617) 430-7577  

Email:   


EN
01/06/2023

Underlying

ASLNAslan Pharmaceuticals ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aslan Pharmaceuticals ADS

 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation...

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company’s development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, Ju...

July 17, 2024 1 EN
 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determinat...

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company’s non-compliance with the ...

July 15, 2024 1 EN
 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary sha...

June 14, 2024 1 EN
 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Ebl...

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations Results support further investigation of eblasakimab as a potential therapeutic option for COPD with potentially more effective blockade of Type-2 mediate...

May 21, 2024 1 EN
 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and...

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. On track to report to...

May 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch